Moderna Puts Its First Seasonal Flu Vaccine In The Clinic

Moderna Inc MRNA has initiated a Phase 1/2 study and dosed the first patient with mRNA1010, its quadrivalent vaccine for seasonal flu.
The candidate is designed to target lineup lineages that include influenza A H1N1, H3N2, and influenza B Yamagata and Victoria.
The 180-subject study will evaluate the safety, reactogenicity, and immunogenicity of mRNA-1010.
Piper Sandler analyst Edward Tenthoff reiterates an Overweight rating on Moderna with a $246 price target after initiating a Phase 1 study of mRNA-1010.
Moderna could "revolutionize" the seasonal flu vaccine market where today's protection rates are only 40%-60%, Tenthoff writes in a research note.
Ultimately Moderna envisions developing a respiratory vaccine that protects against seasonal flu, Covid, and respiratory syncytial virus, says the analyst.
Price Action: MRNA shares are down 4.95% at $221.80 during the market session on the last check Wednesday.

Momentum4.78

Growth13.77

Quality-

Value64.57

Short

Medium

Long

Analyst Calendar